Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy
NCT07436364Phase 1Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren lipid microspheres in soft tissue sarcoma (STS), sponsored by Thomas Jefferson University. Primary endpoint: Success of US-CT/MRI fusion at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
perflutren lipid microspheres
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07436364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436364.